. 2009 Sep 23;39(2):563–577. doi: 10.1093/ije/dyp288

Table 2.

Association of rs16969968 with smoking quantity in CPD

		Controls				LC cases				UADT cancer cases				Cases and controls combined
Study	Genotype	n	Mean	95% CI	P-trend	n	Mean	95% CI	P-trend	n	Mean	95% CI	P-trend	n	Mean	95% CI	P-trend
All	GG	2470	12.3	11.9–12.8		1183	15.7	15.2–16.2		1489	16.2	15.5–17		5142	14.1	13.8–14.4
	GA	2493	12.6	12.1–13		1560	15.9	15.4–16.3		1520	16.6	15.8–17.3		5573	14.4	14.1–14.7
	AA	644	13.5	12.7–14.3	0.01	563	16.6	15.9–17.4	0.03	388	17.5	16.3–18.7	0.04	1595	15.3	14.8–15.8	<.0001
	Abs. diff.		1.2				0.9				1.3				1.2
Central Europe	GG	643	12.4	11.7–13.2		580	16	15.3–16.7		280	15.9	14.6–17.2		1503	14.1	13.7–14.6
	GA	691	12.6	11.9–13.3		799	16.3	15.7–16.9		305	15.6	14.5–16.8		1795	14.3	13.8–14.7
	AA	180	12.5	11.4–13.7	0.81	270	16.4	15.5–17.3	0.38	76	17	15.1–19	0.51	526	14.5	13.8–15.2	0.32
	Abs. diff.		0.1				0.4				1.1				0.4
Toronto	GG	87	17.1	14.3–20.4		64	17.6	14.7–21.1						151	17.5	15.4–19.8
	GA	88	15.2	12.7–18		92	18.4	15.8–21.3						180	16.6	14.8–18.6
	AA	25	14.3	10.4–19.8	0.25	25	26.4	19.8–35.1	0.05					50	19.2	15.5–23.9	0.72
	Abs. diff.		−2.8				8.8								1.7
EPIC	GG	532	10.6	10–11.4		309	15.5	14.5–16.5						841	12.8	12.2–13.4
	GA	591	11	10.3–11.7		427	15.6	14.7–16.5						1018	13	12.5–13.6)
	AA	169	11.6	10.4–13	0.16	184	16	14.7–17.4	0.52					353	13.6	12.7–14.6	0.14
	Abs. diff.		1				0.5								0.8
Liverpool	GG	269	11.6	10.5–12.8		160	17.6	16–19.4						429	14.3	13.3–15.3
	GA	248	12.6	11.3–14		154	17.4	15.8–19.1						402	14.9	13.8–16.1
	AA	53	14.2	11.4–17.7	0.08	56	20.2	17.2–23.6	0.28					109	16.8	14.6–19.2	0.05
	Abs. diff.		2.6				2.6								2.5
Hunt/Tromso	GG	78	7.8	6.8–8.8		70	12	10.6–13.5						148	9.6	8.8–10.5
	GA	79	10.1	8.8–11.5		88	12	10.8–13.3						167	10.9	10.1–11.9
	AA	14	11.5	8.5–15.6	0.002	28	12.4	10.3–14.9	0.83					42	11.6	9.8–13.7	0.01
	Abs. diff.		3.7				0.4								2
ARCAGE	GG	446	14.4	13–15.8						512	17	15.8–18.2		958	15.6	14.7–16.5
	GA	504	13.7	12.6–15						690	17	15.9–18.1		1194	15.3	14.5–16.1
	AA	140	15	13–17.3	0.95					199	17.4	15.8–19.2	0.68	339	16	14.8–17.4	0.82
	Abs. diff.		0.6								0.4				0.4
Latin America	GG	415	12.3	11–13.9						697	16.6	15.3–17.9		1112	14.5	13.5–15.5
	GA	292	12.9	11.3–14.7						525	17.4	16.1–18.9		817	15.3	14.2–16.4
	AA	63	16.9	13.6–21	0.02					113	19.1	16.7–21.9	0.03	176	17.8	15.9–20	0.0007
	Abs. diff.		4.6								2.5				3.3
P-heterogeneity between studies					0.01				0.45				0.33				0.06
Males	GG	1878	14.8	14.2–15.5		864	18.3	17.6–18.9		1301	19.4	18.6–20.3		4043	16.8	16.4–17.2
	GA	1890	15.2	14.6–15.8		1139	18.2	17.6–18.7		1323	20	19.2–20.9		4352	17.1	16.7–17.5
	AA	507	16	15–17.1	0.04	392	18.5	17.6–19.5	0.78	331	20.9	19.5–22.3	0.04	1230	17.7	17.1–18.4	0.01
	Abs. diff.^a		1.2				0.2				1.5				0.9
Females	GG	592	9.9	9–10.8		319	12.5	11.6–13.5		188	14.6	12.7–16.8		1099	11.4	10.8–12
	GA	603	9.8	9–10.7		421	13.3	12.4–14.2		197	13.9	12.2–15.8		1221	11.5	10.9–12.1
	AA	137	10.9	9.5–12.5	0.32	171	15.1	13.8–16.6	0.0004	57	16	12.9–19.7	0.75	365	13.2	12.2–14.2	0.003
	Abs. diff.^a		1				2.6				1.4				1.8
P-heterogeneity between sex					0.94				0.003				0.75				0.13

Linear regression analysis of CPD was performed. Means are adjusted for age, sex, country and case/control status for the combined analysis.

^aDifference in CPD between both homozygous variant (AA) and homozygous (GG) genotypes.